HomeAI · summaries
Storia in 2 fonti
AbbVie and Genmab's latest win brings Epkinly closer to label expansion
AbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step closer to a potential label expansion in diffuse large B-cell lymphoma.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL
Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed…
- ·
endpoints.news
AbbVie and Genmab's latest win brings Epkinly closer to label expansion
AbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step closer to a potential label expansion in diffuse…